Heart transplantation in patients with diabetic end-organ damage before transplantation

被引:7
|
作者
Aleksic, I
Czer, LSC
Freimark, D
Dalichau, H
Takkenberg, JJM
Blanche, C
Nessim, S
Nusser, P
Trento, A
机构
[1] UNIV GOTTINGEN, DEPT THORAC, D-3400 GOTTINGEN, GERMANY
[2] UNIV GOTTINGEN, DEPT CARDIOVASC SURG, D-3400 GOTTINGEN, GERMANY
[3] CEDARS SINAI MED CTR, DEPT CARDIOL, LOS ANGELES, CA 90048 USA
[4] CEDARS SINAI MED CTR, DEPT CARDIOTHORAC SURG, LOS ANGELES, CA 90048 USA
[5] CEDARS SINAI MED CTR, DEPT BIOSTAT, LOS ANGELES, CA 90048 USA
来源
THORACIC AND CARDIOVASCULAR SURGEON | 1996年 / 44卷 / 06期
关键词
heart transplantation; diabetes mellitus; end-organ damage;
D O I
10.1055/s-2007-1012038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes mellitus with preexisting end-organ damage (EOD) is considered a contraindication for heart transplantation. The outcome of such patients has not been well characterized. Among 138 patients transplanted between 12/88 and 7/94, 29 were diabetic (11 insulin-dependent); of these, 12 had preexisting EOD, defined as a creatinine clearance less than or equal to 50 ml/min, a 24-hour urine protein concentration greater than or equal to 500 mg/L or typical symptoms of peripheral or autonomic polyneuropathy, and 17 had no EOD. We compared diabetics with and without EOD and nondiabetics (n = 109) for operative mortality, length of stay, serum creatinine, fasting glucose levels, and postoperative prednisone doses at 1,6, and 12 months. Actuarial survival and freedom from rejection and infection were analyzed. Both diabetic groups were significantly older than nondiabetics. Ischemic time, operative mortality, surgical technique, ICU- and total length of stay were similar. Actuarial survival and freedom from rejection were similar among the three groups. Infection rates including CMV did not differ. Serum creatinine levels increased in all groups compared to pretransplant levels (p = 0.001), but without significant differences among the groups. Post-transplant glucose levels at 6 and 12 months were higher for diabetic patients with EOD than for those without or for nondiabetics (183, 153, and 94 mg/dl at 6 months, p = 0.01; 202, 161, and 102 mg/dl at 12 months, p = 0.0001). Prednisone dosage was lower in diabetics with EOD at 6 months, but did not differ among the three groups at 12 months. The incidence of angiographically proven transplant vasculopathy did not differ at 1 and 2 years. Diabetics with preexisting EOD undergoing heart transplantation experience similar short- and intermediate-term results when compared to diabetics without EOD and nondiabetics. Metabolic control is more difficult to achieve, as indicated by higher fasting glucose levels. Larger and longer-term prospective studies have to confirm our findings, since the shortage of donor organs would increase if such patients were transplanted routinely.
引用
收藏
页码:282 / 288
页数:7
相关论文
共 50 条
  • [31] Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure
    Mori, Takefumi
    Ohsaki, Yusuke
    Oba-Yabana, Ikuko
    Ito, Sadayoshi
    HEPATOLOGY RESEARCH, 2017, 47 (01) : 11 - 22
  • [32] Hypertensive Heart Failure: Sprinting to the Finish Line to Prevent End-Organ Damage Preface
    Baliga, Ragavendra R.
    Bossone, Eduardo
    Bakris, George L.
    HEART FAILURE CLINICS, 2019, 15 (04) : XIII - XV
  • [33] END-ORGAN DAMAGE IN ESSENTIAL-HYPERTENSION IN THE ELDERLY
    KOHARA, K
    HIWADA, K
    JOURNAL OF HUMAN HYPERTENSION, 1995, 9 (09) : 717 - 721
  • [34] The role of angiotensin II in hypertension and end-organ damage
    Pool, JL
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2000, : 4 - 8
  • [35] Pulse Pressure, Arterial Stiffness, and End-Organ Damage
    Michel E Safar
    Peter M Nilsson
    Jacques Blacher
    Albert Mimran
    Current Hypertension Reports, 2012, 14 : 339 - 344
  • [36] Pulse Pressure, Arterial Stiffness, and End-Organ Damage
    Safar, Michel E.
    Nilsson, Peter M.
    Blacher, Jacques
    Mimran, Albert
    CURRENT HYPERTENSION REPORTS, 2012, 14 (04) : 339 - 344
  • [37] First study with valsartan (Diovan) to prevent end-organ damage in patients with diabetes
    不详
    SOUTH AFRICAN MEDICAL JOURNAL, 1999, 89 : C285 - C286
  • [38] ORGAN PERFUSION BEFORE TRANSPLANTATION
    BLOCH, JH
    LILLEHEI, RC
    MANAX, WG
    FEDERATION PROCEEDINGS, 1964, 23 (2P1) : 237 - &
  • [39] Reducing Cardiovascular Events and End-Organ Damage in Patients with Hypertension: New Considerations
    Harmon, Laura
    Chilton, Robert J.
    Spellman, Craig
    POSTGRADUATE MEDICINE, 2011, 123 (02) : 7 - 17
  • [40] Reactive Oxygen Comes of Age: Mechanism-Based Therapy of Diabetic End-Organ Damage
    Elbatreek, Mahmoud H.
    Pachado, Mayra P.
    Cuadrado, Antonio
    Jandeleit-Dahm, Karin
    Schmidt, Harald H. H. W.
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2019, 30 (05): : 312 - 327